Vivalis SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Vivalis SA Issues FY 2013 Revenue Guidance
Vivalis SA announced that it expects its revenue to increase for full year 2013 compared to full year 2012 as a result of its commercial strategy. The Company reported full year 2012 revenue of EUR 3.43 million.
Latest Developments for Vivalis SA
- Vivalis SA Announces Update on Merger with Intercell AG and Planned Name Change to Valneva
- Vivalis SA Announces Effective Date of Merger of Equals Between Vivalis SA and Intercell AG to Create Valneva; Shareholders of Both Parties Give Approval
- Intercell AG Approves Proposed Merger of Equals with Vivalis SA to Create Valneva SE
- Intercell AG and Vivalis SA to Merge and to Form Valneva SE
Latest Key Developments in Biotechnology
- Apricus Biosciences Inc Prices $17.1 Million Public Offering Of Common Stock And Warrants
- Stemline Therapeutics Inc Announces Exercise Of Option To Purchase Additional Shares
- Omeros Corp Announces Clearence Of New Drug Application By FDA For OMS824 In Huntington's Disease
- Miraca Holdings Inc Appoints Corporate Auditor
- Share this
- Digg this